FDA moves on GLP‑1 compounding

GLP-1 compounding just got a lot more precarious. On April 30, the FDA said it wants semaglutide, tirzepatide, and liraglutide excluded from the 503B bulks list — the list that can let outsourcing facilities make compounded drugs from raw active ingredients. The practical effect is simple: if this sticks, large-scale compounders have a much narrower path to keep making copycat weight-loss shots from bulk powder. (fda.gov) And this is landing after the agency already said national supply of these drugs had stabilized enough to tighten compounding rules. ### What is the 503B bulks list? It is basically the FDA’s gate for large outsourcing facilities. A 503B facility can compound from bulk drug substances only in limited cases — mainly if the ingredient is on the 503B bulks list or the finished drug is on the FDA shortage list at the time of compounding, distribution, and dispensing. (fda.gov) That is why this list matters so much for GLP-1s. ### What changed last week? The FDA published a notice proposing not to include semaglutide, tirzepatide, and liraglutide on that list. The agency said it reviewed the nominations for all three and did not find a clinical need for outsourcing facilities to compound them from bulk substances. This is still a proposal, not the final word, but it is a very clear signal about where the agency wants to land. (fda.gov) ### Why does “no clinical need” matter? Because that phrase is the hinge. If FDA-approved versions are available, 503B facilities generally cannot lawfully make compounded versions from raw ingredients unless there is a recognized clinical need or an active shortage exception. The FDA is saying, in plain terms, that these blockbuster GLP-1s do not meet that bar for bulk compounding. (fda.gov) ### Why now? Because the shortage era is fading. The FDA has already told compounders that national GLP-1 supply has begun to stabilize and reminded them that copies of commercially available drugs face strict limits under both 503A and 503B. The agency even spelled out that semaglutide mixes with add-ons like vitamin B12 can still be treated as essentially copies in many cases. (fda.gov) In other words — FDA is not just ending the emergency vibe, it is narrowing the workarounds too. ### Does this ban all compounding? No. Patient-specific compounding under 503A can still exist in narrow circumstances, especially where a prescriber documents a significant clinical difference for an individual patient. But the easy model — bulk ingredient in, mass-produced alternative out — is exactly what this proposal is aimed at. (fda.gov) That is why big telehealth-style supply chains should pay attention. ### What does this mean for patients? More friction, basically. If someone has been getting compounded semaglutide or tirzepatide through a clinic, med spa, or online prescriber, the source of that medication may matter a lot more soon. Patients may need to shift to branded supply, qualify for a narrower compounding exception, or stop treatment if cost or access breaks the chain. (fda.gov) That is not a hypothetical administrative issue — it changes refill risk. ### Why is adherence part of this story? Because GLP-1 use is already unstable even before supply rules tighten. A Danish real-world study highlighted in 2025 found that more than half of first-time semaglutide users without diabetes stopped within a year, with 18% stopping by 3 months, 31% by 6 months, and 42% by 9 months. (fda.gov) So clinics are dealing with two moving targets at once — where patients get the drug, and whether they are still actually taking it. ### What happens next? The public comment window runs through June 30, 2026. After that, the FDA will decide whether to finalize the exclusion. The bottom line is pretty clear already, though — the agency is trying to close the chapter where compounded GLP-1s functioned like a parallel mass market beside Novo Nordisk and Eli Lilly’s approved products. (fda.gov) (federalregister.gov) (ajmc.com)